COMMUNIQUÉS West-GlobeNewswire

Invitation to Participate in STOP-PC Clinical Trial
04/03/2024
AGOURA HILLS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) invites participation in our STOP-PC clinical trial which is now open for recruitment. Additional information can be [...]
Molecular Templates, Inc. Provides Interim Update
04/03/2024
Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase I study AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- [...]
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
04/03/2024
The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation of DMT VLS-01 is being developed as a rapid-acting [...]
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
04/03/2024
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody ® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 ZUG, Switzerland, March 4, 2024 – MoonLake Immunotherapeutics [...]
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
04/03/2024
VANCOUVER, British Columbia, March 04, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and [...]
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
04/03/2024
CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction in non-fatal major [...]
Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology in Duchenne Muscular Dystrophy at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
04/03/2024
Bobcat mRNA TM technology is a novel linear mRNA platform able to encode large proteins Data showed restoration of muscular function in DMD mouse model BALTIMORE, March 04, 2024 (GLOBE NEWSWIRE) -- Elixirgen [...]
Tome Biosciences Forms Science and Technology Advisory Committee
04/03/2024
WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc. , the programmable genomic integration (PGI) company, announces the formation of its Science and Technology Advisory Committee (STAC) comprised [...]
4DMT to Participate in Upcoming Investor Conferences
04/03/2024
EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic [...]
Aruna BIO Establishes Stroke Advisory Board to Advance Lead Program, AB126 into the Clinic
04/03/2024
-The Stroke Advisory Board brings together distinguished experts in neurology and stroke to support the advancement of its neural exosome platform and lead program– -Phase 1b/2a clinical trial in acute ischemic stroke [...]
Vor Bio to Participate in Upcoming Investor Conferences
04/03/2024
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: [...]
Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024
04/03/2024
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of [...]
Osmol Therapeutics Appoints Ron Weitzman, M.D., as Interim Chief Medical Officer
04/03/2024
Company plans to initiate clinical program in mid-2024, followed by a Phase 2 study for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in patients with breast cancer NEW HAVEN, Conn., March 04, 2024 [...]
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
04/03/2024
MAA Validation Follows Recent Applications for Seladelpar to the U.K. MHRA and U.S. FDA NEWARK, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused [...]
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
04/03/2024
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of [...]
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs
04/03/2024
Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better [...]
First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering
04/03/2024
BOCA RATON, Fla., March 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of [...]
Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024
04/03/2024
DURHAM, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for [...]
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
04/03/2024
Clearance to include teen patients in both the company’s open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment and lead to a more [...]

Pages